Skip to content

Fresenius Medical Care postpones 2020 Annual General Meeting

| Press release

Press Release

Fresenius Medical Care, the world’s leading provider of dialysis products and services, postpones its 2020 Annual General Meeting, which was scheduled for May 19, to a later date this year due to the coronavirus pandemic. The resolutions regarding the allocation of the distributable profit and the payout of the dividend will be postponed accordingly.

As soon as conditions allow again for a reliable planning and safe implementation of the Annual General Meeting, Fresenius Medical Care will announce the new date.

Rice Powell, Chief Executive Officer of Fresenius Medical Care, said: “The decision to postpone our Annual General Meeting was not an easy one for us to take. But the protection and health of our shareholders and employees is very important to us. In light of this exceptional situation, a postponement is the only sensible option.”

 

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,994 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 345,096 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.